samedan logo
 
 
spacer
home > ict > autumn 2017 > shredding paper
PUBLICATIONS
International Clinical Trials

Shredding Paper

The informed consent process represents the keystone in a
clinical trial, the space where science meets the patient. As
healthcare began to globalise in the 1990s and 2000s, process
and presentation flexibility became crucial. With technology
spreading around the globe, the defects and difficulties in the
use of text-only documents, reported internationally for 30
years, became even more apparent. Patients worldwide decreed
that text-only paper consent forms were confusing, hard to
and sometimes in different languages. Patients frequently
breezed through paper forms without truly understanding
the material and were surprised by aspects of the trial once it
started. This led to frustration and subjects often dropped out
of the consent process or the trial itself.

With the globalisation of clinical research, creating a flexible
system that works across international boundaries, yet respects
the differences of countries and regions, is imperative.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Eric Delente, President at DrugDev Patient Solutions, has more than 20 years of experience leading technical and creative teams in the design and implementation of numerous award-winning online science, healthcare and clinical research web applications. Most recently, he led SecureConsent, the industry’s definitive eConsent solution.
spacer
Eric Delente
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Klöckner Pentaplast to introduce latest shrink label technologies and delivery master class at Labelexpo Americas 2016


More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2017

28-29 November 2017, RAI, Amsterdam

PCT Europe is back, bringing you the latest information from across the clinical trials spectrum and providing you with direct access to the industry's leading innovators. And this year, we're in Amsterdam!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement